Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Letters: Observations

Safety Issues on Metformin Use

  1. Saleh A. Aldasouqi, MD1 and
  2. Daniel S. Duick, MD2
  1. 1King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia
  2. 2Endocrinology Associates, Phoenix, Arizona
  1. Address correspondence to Saleh A. Aldasouqi, MD, King Fahd Miltary Teaching Hospital, P.O. Box 9862, Jeddah 21159, Saudi Arabia. E-mail: saldasouqi{at}pol.net
Diabetes Care 2003 Dec; 26(12): 3356-3357. https://doi.org/10.2337/diacare.26.12.3356
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

We read with interest the letter by Faichney and Tate (1) in the May issue of Diabetes Care. We would like to comment on metformin and the risk of lactic acidosis; however, we do not have data to refute the hypothetical relevance of diabetic ketoacidosis to the risk of lactic acidosis (1). We believe that the aforementioned letter and relevant reports (2–4) may negatively affect the future use of metformin, not only in type 1 (1) but also in type 2 diabetic patients. In this regard, the report by Horlen et al. (2), which addressed physicians’ lack of adherence to metformin prescribing precautions, was received with strong opposition in the medical media (5) following the public support from the Associated Press (www.aace.com).

Lactic acidosis has been linked to the use of biguanides for decades. Although phenformin had been pulled from the market, metformin-associated lactic acidosis has since been believed to be the direct result of metformin use, especially in situations likely to precipitate lactic acidosis, e.g., congestive heart failure, chronic renal insufficiency, shock, etc. Although this “solid fact” of causative (etiologic) relation between metformin and lactic acidosis has not been challenged previously, recent relevant publications have appeared in the literature (6–8). Lalau and colleagues (6,7) found that metformin accumulation was not related to either lactic acidosis or the associated mortality in patients taking therapeutic doses of metformin who developed lactic acidosis in association with other precipitating conditions. Metformin overdose was an exception, they reported (6); the latter can cause genuine type B lactic acidosis, but only a few such cases have been reported (9). In the report on metformin-associated lactic acidosis published by FDA investigators (3), metformin levels were not measured.

Rachmani et al. (8) have recently reported no lactic acidosis in diabetic patients who were continued on metformin over 4 years of follow-up; these patients had traditional contraindications (congestive heart failure, chronic renal insufficiency, or chronic obstructive pulmonary disease) to metformin use. Furthermore, a recent meta-analysis of 176 studies with >35,000 patient-years of follow-up found no cases of lactic acidosis, although some of these studies included patients with renal insufficiency and cardiovascular conditions (4).

Finally, Jones and Macklin (10) have recently reported that evidence suggested it was time to amend the contraindication “list” of metformin prescribing. They pointed out that the limiting criteria for the use of metformin in diabetes had stemmed largely from reports in the 1970s of mortality and lactic acidosis associated with “phenformin.”

Therefore, one may wonder whether metformin is an “innocent bystander” in these clinically complex metformin-associated lactic acidosis cases.

In conclusion, in view of the aforementioned thoughts challenging the “apparently well-established” etiologic role of metformin in metformin-associated lactic acidosis, and pending further research, it is prudent to critically appraise published reports on the issue. We believe that the average dose of metformin currently used in clinical practice is reasonably safe, even in the presence of mild to moderate cases of the “traditional contraindications.” An exception to this is the safe practice of holding metformin before contrast studies and during acute, intercurrent illnesses.

Footnotes

  • DIABETES CARE

References

  1. ↵
    Faichney JD, Tate PW: Metformin in type 1 diabetes: is this a good or bad idea? (Letter). Diabetes Care 26:1655, 2003
    OpenUrlFREE Full Text
  2. ↵
    Horlen C, Malone R, Bryant B, Dennis B, Carey T: Frequency of inappropriate metformin prescriptions (Letter). JAMA 287:2504–2505, 2002
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA: Lactic acidosis in patients with diabetes treated with metformin (Letter). N Engl J Med 338:265–266, 1998
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM: Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 290:81–85, 2003
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    The American Association of Clinical Endocrinologists calls for patients with diabetes to take charge of their health [article online], 2002. Available from http://www.aace.com/pub/press/releases/index.php?r=20020517. Accessed 22 May 2002
  6. ↵
    Lalau JD, Lacroix C, Compagnon P, De Cagny B, Rigaud JP, Bleichner G, Chauveau P, Dulbecco P, Guerin C, Haegy JM, Loirat P, Marchand B, Rvaud Y, Weyne P, Fournier A: Role of metformin accumulation in metfornin-associated lactic acidosis. Diabetes Care 18:779–784, 1995
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Lalau JD, Race JM: Lactic acidosis in metformin therapy: searching for a link with metformin in reports of “metformin-associated lactic acidosis.” Diabetes Obes Metab 3:195–201, 2001
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Rachmani R, Slavachevski I, Levi Z, Zadok BS, Kedar Y, Ravid M: Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. European J Int Med 13:428–433, 2002
    OpenUrl
  9. ↵
    Teale KF, Devine A, Stewart H, Harper NJ: The management of metformin overdose. Anesthesia 53:698–701, 1998
    OpenUrl
  10. ↵
    Jones GC, Macklin JP: Contraindications to the use of metformin: evidence suggests that it is time to amend the list. BMJ 326:4–5, 2000
    OpenUrl
PreviousNext
Back to top
Diabetes Care: 26 (12)

In this Issue

December 2003, 26(12)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety Issues on Metformin Use
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Safety Issues on Metformin Use
Saleh A. Aldasouqi, Daniel S. Duick
Diabetes Care Dec 2003, 26 (12) 3356-3357; DOI: 10.2337/diacare.26.12.3356

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Safety Issues on Metformin Use
Saleh A. Aldasouqi, Daniel S. Duick
Diabetes Care Dec 2003, 26 (12) 3356-3357; DOI: 10.2337/diacare.26.12.3356
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Weight Gain and Gestational Diabetes Mellitus Is a Sensitive Issue
  • Beneficial Effects of a 4-Week Exercise Program on Plasma Concentrations of Adhesion Molecules
  • Malignant Melanoma Misdiagnosed as a Diabetic Foot Ulcer
Show more Letters: Observations

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.